William Nevers1, Alice Ratcheva2, Kate Boutin3, Sean K Gorman4, Richard Slavik5, Natalie Lesko6. 1. , BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacy Specialist - Critical Care and Emergency Medicine, Kelowna General Hospital, Kelowna, British Columbia. 2. , BSc(Pharm), is a Pharmacy Practice Resident, Interior Health Pharmacy Practice Residency Program, Kelowna General Hospital, Kelowna, British Columbia. 3. , BSc, BSc(Pharm), ACPR, is a Clinical Pharmacist, Pharmacy Services, Kelowna General Hospital, Kelowna, British Columbia. 4. , BSc(Pharm), ACPR, PharmD, is Regional Coordinator - Clinical Quality and Research and Pharmacotherapeutic Specialist - Critical Care, Kelowna General Hospital, Kelowna, British Columbia; and is also a Clinical Associate Professor, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. 5. , BSc(Pharm), ACPR, PharmD, FCSHP, is Regional Manager, Pharmacy Professional Practice, and Pharmacotherapeutic Specialist - Critical Care, Kelowna General Hospital, Kelowna, British Columbia; and is also a Clinical Professor, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. 6. , BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacy Specialist - Nephrology, Kelowna General Hospital, Kelowna, British Columbia.
Abstract
BACKGROUND: Previous studies have shown that patients with chronic kidney disease who are followed by a renal clinical pharmacist have improved clinical outcomes. In 2016, a consensus list of quality indicator drug therapy problems (QI-DTPs) was developed by renal clinical pharmacists to help prioritize which renal patients should receive interventions. Before QI-DTP interventions can be implemented in clinical practice, barriers to and enablers of their use need to be identified, to allow development of strategies to overcome the barriers and apply the enablers. OBJECTIVE: To identify modifiable barriers to and enablers of implementation of renal QI-DTP interventions by renal clinical pharmacists. METHODS: In this exploratory qualitative descriptive study, one-on-one, semistructured, audio-recorded telephone interviews were conducted with renal clinical pharmacists to identify the barriers to and enablers of implementation of renal QI-DTP interventions. The interviews consisted of questions developed according to the Theoretical Domains Framework. RESULTS: Interviews were conducted with 13 renal pharmacists from across Canada. The main barriers to implementation of renal QI-DTP interventions that participants identified were knowledge gaps, prioritization, and nephrologist acceptance. The main enablers identified were training, colleague support, and better patient care. CONCLUSION: Three barriers to and three enablers of implementation of renal QI-DTP interventions were identified. These barriers and enablers can be used to help with pharmacist education and to optimize the care that pharmacists provide to renal patients. 2020 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
BACKGROUND: Previous studies have shown that patients with chronic kidney disease who are followed by a renal clinical pharmacist have improved clinical outcomes. In 2016, a consensus list of quality indicator drug therapy problems (QI-DTPs) was developed by renal clinical pharmacists to help prioritize which renal patients should receive interventions. Before QI-DTP interventions can be implemented in clinical practice, barriers to and enablers of their use need to be identified, to allow development of strategies to overcome the barriers and apply the enablers. OBJECTIVE: To identify modifiable barriers to and enablers of implementation of renal QI-DTP interventions by renal clinical pharmacists. METHODS: In this exploratory qualitative descriptive study, one-on-one, semistructured, audio-recorded telephone interviews were conducted with renal clinical pharmacists to identify the barriers to and enablers of implementation of renal QI-DTP interventions. The interviews consisted of questions developed according to the Theoretical Domains Framework. RESULTS: Interviews were conducted with 13 renal pharmacists from across Canada. The main barriers to implementation of renal QI-DTP interventions that participants identified were knowledge gaps, prioritization, and nephrologist acceptance. The main enablers identified were training, colleague support, and better patient care. CONCLUSION: Three barriers to and three enablers of implementation of renal QI-DTP interventions were identified. These barriers and enablers can be used to help with pharmacist education and to optimize the care that pharmacists provide to renal patients. 2020 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Authors: Katherine Boutin; William Nevers; Sean K Gorman; Richard S Slavik; Daniel J Martinusen; Clifford Lo Journal: Int J Pharm Pract Date: 2018-09-12
Authors: Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi Journal: CMAJ Date: 2013-05-06 Impact factor: 8.262
Authors: Laura V Minard; Heidi Deal; Megan E Harrison; Kent Toombs; Heather Neville; Andrea Meade Journal: PLoS One Date: 2016-04-04 Impact factor: 3.240
Authors: Paula Elouafkaoui; Linda Young; Rumana Newlands; Eilidh M Duncan; Andrew Elders; Jan E Clarkson; Craig R Ramsay Journal: PLoS Med Date: 2016-08-30 Impact factor: 11.069